Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Public ClinicalTrials.gov record NCT06106308. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.
Study identification
- NCT ID
- NCT06106308
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 110 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 27, 2024 (Actual)
- Primary completion
- Nov 2026 (Estimated)
- Completion
- Jan 2027 (Estimated)
- Last update posted
- Jun 16, 2026
2024 – 2027
United States locations
- U.S. sites
- 41
- U.S. states
- 21
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic - Arizona | Phoenix | Arizona | 85054 | — |
| The University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| St. Bernards Medical Center | Jonesboro | Arkansas | 72401 | — |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| Pacific Cancer Medical Center | Anaheim | California | 92801 | — |
| Comprehensive Blood and Cancer Center - Bakersfield | Bakersfield | California | 93309 | — |
| Orange Coast Memorial Medical Center | Fountain Valley | California | 92708 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92037 | — |
| Norris Comprehensive Cancer Center | Los Angeles | California | 90089 | — |
| UCLA Department of Medicine-Hematology/Oncology | Los Angeles | California | 90095 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| Torrance Memorial Physician Network - Cancer Care and Infusion Center | Torrance | California | 90505 | — |
| PIH Health | Whittier | California | 90602 | — |
| Memorial Cancer Institute | Hollywood | Florida | 33021 | — |
| Mayo Clinic - Florida | Jacksonville | Florida | 32224 | — |
| Cleveland Clinic Martin Health | Stuart | Florida | 34994 | — |
| Kaiser Permanente | Honolulu | Hawaii | 96819 | — |
| Fort Wayne Medical Oncology and Hematology | Fort Wayne | Indiana | 46804 | — |
| The University of Kansas Cancer Center - Westwood | Westwood | Kansas | 66205 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | — |
| Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion | Grand Rapids | Michigan | 49503 | — |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905 | — |
| Saint Luke's Hospital | Kansas City | Missouri | 64111 | — |
| Washington University School of Medicine Center for Advanced Medicine | St Louis | Missouri | 63110 | — |
| CCCN | Las Vegas | Nevada | 89119 | — |
| Manhattan Hematology Oncology (MHO) Research Foundation, Inc. | New York | New York | 10016 | — |
| Trihealth Kenwood | Cincinnati | Ohio | 45242 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Lehigh Valley Health Network | Allentown | Pennsylvania | 18103 | — |
| West Cancer Clinic | Germantown | Tennessee | 38138 | — |
| Oncology Consultants, PA | Houston | Texas | 77024 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84124 | — |
| University of Virginia | Charlottesville | Virginia | 22908 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| VCU Massey Cancer Center | Richmond | Virginia | 23298 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| ThedaCare Regional Cancer Center | Appleton | Wisconsin | 54911 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06106308, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06106308 live on ClinicalTrials.gov.